ClinicalTrials.gg
Active, not recruitingNCT05625399RELATIVITY-127Updated Aug 26, 2026Results posted

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

A Phase 3 interventional study of Nivolumab + Relatlimab and rHuPH20 in Melanoma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 149 sites in 19 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
579
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 63 under way, 9 of them phase 3. Nivolumab · Melanoma.

Enrollment
9th of 142
579 · median 50
Started
2023
with 11 others
Phase 3
19 of 142
2 open now
Primary completion
2025-08
later than 18 of 62 live
Registered
108th of 142
by date
Lead sponsor
23 of 142
Bristol-Myers Squibb

Among the 142 studies testing nivolumab in Melanoma, this one is the 9th largest by enrollment, is one of 12 that started in 2023, is one of 19 in phase 3, reaches primary completion later than 18 of the 62 other live ones, and was the 108th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing nivolumab in Melanoma, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • Nivolumab
  • Relatlimab
  • FDC
  • Melanoma
  • rHuPH20
  • OPDUALAG
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have an (ECOG) performance status of ≤ 1/Lansky Performance Score ≥ 80% for adolescents (≥ 12 to \< 18 years of age).
  • Participants must have confirmed Stage III (unresectable) or Stage IV () melanoma, per the American Joint Committee for Cancer (AJCC) staging system.
  • Participants must have by computed tomography (CT) or magnetic resonance imaging (MRI) per version 1.1 (RECIST v1.1).
  • Participants must be ≥ 12 years of age. Participants who are ≥ 12 years of age and \< 18 years of age (adolescents) must weigh ≥ 40 kg at the time of signing the (assent).
  • Participants must have histologically confirmed Stage III (unresectable) or Stage IV (metastatic) melanoma, per the AJCC staging system (8th edition).

Exclusion criteria

Exclusion Criteria

  • Participants must not have ocular melanoma.
  • Participants must not have a history of myocarditis, regardless of etiology.
  • Participants must not have a condition requiring systemic treatment with either (>10 milligrams [mg] daily prednisone equivalent) or other medications within 14 days of start of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses >10 mg daily prednisone equivalent, are permitted in the absence of active disease.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
579 participants (actual)

Study arms

  • Experimental
    Nivolumab + Relatlimab FDC SC

    Drug: Nivolumab + Relatlimab · Drug: rHuPH20

  • Active comparator
    Nivolumab + Relatlimab FDC IV

    Drug: Nivolumab + Relatlimab

Interventions

  • DrugNivolumab + Relatlimab

    Drug pages: Nivolumab · Relatlimab

    Specified dose on specified days

    Also known as: BMS-986213, Opdualag

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale

    Blood samples were collected to assess serum concentration.

    Time frame: Pre-dose (Day 1 to Day 28)

  2. Adjusted Time-Averaged Relatlimab Serum Concentration Over the First 28 Days (Cavgd28-Rela) on Natural Logarithmic Scale

    Blood samples were collected to assess serum concentration.

    Time frame: Pre-dose (Day 1 to Day 28)

  3. Adjusted Trough Nivolumab Serum Concentration at Steady-State (Cminss-Nivo) on Natural Logarithmic Scale

    Blood samples were collected to assess serum concentration.

    Time frame: Pre-dose (Day 1 to Day 28)

  4. Adjusted Trough Relatlimab Serum Concentration at Steady-State (Cminss-Rela) on Natural Logarithmic Scale

    Blood samples were collected to assess serum concentration.

    Time frame: Pre-dose (Day 1 to Day 28)

Secondary outcomes

  1. Objective Response Rate (ORR) by BICR

    Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)

  2. Disease Control Rate (ORR) Per BICR

    Disease control rate (DCR) is defined as the percentage of participants who achieve a BOR of confirmed Complete Response (CR), confirmed Partial Response (PR), or stable disease (SD), based on BICR assessments (using RECIST 1.1) divided by the number of all randomized participants. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)

  3. Time to Response (TTR) Per BICR

    Time to response (TTR) assessed by BICR is defined as the time between the date of randomization and the first confirmed documented response (CR or PR) per RECIST 1.1 criteria. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)

  4. Duration of Response (DoR) Per BICR

    Duration of Response (DOR) in months is defined as the time from date of the first documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. CR is complete disappearance of all target lesions except nodal disease; all target nodes must decrease to normal size (short axis \< 10 mm). PR is ≥30% decrease under baseline of the sum of diameters of all target measurable lesions. Disease progression is defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)

  5. Progression Free Survival Per BICR

    Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)

  6. Objective Response Rate (ORR) Per Investigator

    Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on Investigator assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)

  7. Disease Control Rate (ORR) Per Investigator

    Disease control rate (DCR) is defined as the percentage of participants who achieve a BOR of confirmed Complete Response (CR), confirmed Partial Response (PR), or stable disease (SD), based on Investigator assessments (using RECIST 1.1) divided by the number of all randomized participants. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)

  8. Time to Response (TTR) Per Investigator

    Time to response (TTR) assessed by Investigator is defined as the time between the date of randomization and the first confirmed documented response (CR or PR) per RECIST 1.1 criteria. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)

  9. Duration of Response (DoR) Per Investigator

    Duration of Response (DOR) in months is defined as the time from date of the first documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. CR is complete disappearance of all target lesions except nodal disease; all target nodes must decrease to normal size (short axis \< 10 mm). PR is ≥30% decrease under baseline of the sum of diameters of all target measurable lesions. Disease progression is defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)

  10. Progression Free Survival Per Investigator

    Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)

  11. Overall Survival (OS)

    Overall survival is defined as the time from the first dosing date (or from randomization/on treatment) to the date of death from any cause. Median computed using Kaplan-Meier method.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)

  12. Trough Serum Concentration of Nivolumab and Relatlimab (Cmind28) at Day 28

    Blood samples were collected to assess serum concentration.

    Time frame: Pre-dose at Day 28

  13. Peak Serum Concentration (Cmax1) After the First Dose of Nivolumab and Relatlimab

    Blood samples were collected to assess serum concentration.

    Time frame: Post-dose Day 1

  14. Maximum Observed Concentration at Steady State (Cmaxss) Nivolumab and Relatlimab

    Blood samples were collected to assess serum concentration.

    Time frame: Post-dose Day 1

  15. Average Observed Concentration at Steady State (Cavgss) of Nivolumab and Relatlimab

    Blood samples were collected to assess serum concentration.

    Time frame: Post-dose Day 1

  16. Number of Participants With Adverse Events, SAEs, AEs Leading to Discontinuation and Deaths

    AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence at any dose that: results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity or substantial disruption of the ability to conduct normal life functions, results in a congenital abnormality or birth defect, or is an important medical event that may not result in death, be life-threatening, or require hospitalization, but may require medical or surgical intervention to prevent any of the outcomes listed above.

    Time frame: First dose (Day 1) and 30 days after last dose of study therapy (up to approximately 26 months)

  17. Number of Participants With Immune-mediate Adverse Events (IMAEs)

    AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment.

    Time frame: First dose (Day 1) and 135 days after last dose of study therapy (up to approximately 29 months)

  18. Number of Participants With Other Event of Special Interest (OESI)

    AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment.

    Time frame: First dose (Day 1) and 100 days after last dose of study therapy (up to approximately 28 months)

  19. Number of Participants With On-Treatment Worst CTCAE Grade 3-4 Laboratory Parameters

    AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment.

    Time frame: First dose (Day 1) and 30 days after last dose of study therapy (up to approximately 26 months)

  20. Change From Baseline Functional Assessment of Cancer Therapy -Melanoma (FACT-M) Total Score

    The FACT-M questionnaire was used to assess the effects of disease symptoms on functioning and well-being. As a generic cancer-related core, the FACT-M includes the 27-item FACT General (FACT-G) to assess physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). In addition, the FACT-M includes a 16-item disease-specific Melanoma Subscale (MS). Each FACT-M item is rated on a 5-point scale ranging from 0 (not at all) to 4 (very much). Scores for the PWB, FWB, SWB, and EWB subscales can be combined to produce a FACT-G total score, which provides an overall indicant of generic quality of life, while the FACT-G and MS scores can be combined to produce a total score for the FACT-M, which provides a composite measure of general and targeted quality of life. Overall scale ranges from 0 to 172, higher values indicate better functioning as well as lower symptom burden.

    Time frame: Baseline (Day 1) and Week 85

07

Results

Posted Aug 26, 2026

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestoneNivo + Rela FDC SCNivo + Rela FDC IV
Started286292
Completed283291
Not completed31
Withdrew: Full withdrawal of consent by subject from study10
Withdrew: Subject no longer meets study criteria21
Treatment Period
Participant flow — Treatment Period
MilestoneNivo + Rela FDC SCNivo + Rela FDC IV
Started283291
Completed00
Not completed283291
Withdrew: Other reasons10
Withdrew: Partial withdrawal of consent by subject01
Withdrew: Withdrawal of consent by subject from treatment period34
Withdrew: Full withdrawal of consent by subject from study24
Withdrew: Symptomatic deterioration810
Withdrew: Subject request to discontinue study treatment01
Withdrew: Progressive disease10893
Withdrew: Adverse event4968
Withdrew: Ongoing treatment112110

Outcome measures

PrimaryAdjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale

Blood samples were collected to assess serum concentration.

Time frame:
Pre-dose (Day 1 to Day 28)
Reported as:
Mean · ug/mL
Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale
ug/mLNivo + Rela FDC SCNivo + Rela FDC IV
Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale4.141 ± 0.01673.901 ± 0.0164
Statistical analysis
  • Nivo + Rela FDC SC vs Nivo + Rela FDC IV · Adjusted mean difference: 0.239 · 90% CI 0.202 to 0.277
PrimaryAdjusted Time-Averaged Relatlimab Serum Concentration Over the First 28 Days (Cavgd28-Rela) on Natural Logarithmic Scale

Blood samples were collected to assess serum concentration.

Time frame:
Pre-dose (Day 1 to Day 28)
Reported as:
Mean · ug/mL
Adjusted Time-Averaged Relatlimab Serum Concentration Over the First 28 Days (Cavgd28-Rela) on Natural Logarithmic Scale
ug/mLNivo + Rela FDC SCNivo + Rela FDC IV
Adjusted Time-Averaged Relatlimab Serum Concentration Over the First 28 Days (Cavgd28-Rela) on Natural Logarithmic Scale3.120 ± 0.01862.721 ± 0.0183
Statistical analysis
  • Nivo + Rela FDC SC vs Nivo + Rela FDC IV · Adjusted mean difference: 0.398 · 90% CI 0.356 to 0.440
PrimaryAdjusted Trough Nivolumab Serum Concentration at Steady-State (Cminss-Nivo) on Natural Logarithmic Scale

Blood samples were collected to assess serum concentration.

Time frame:
Pre-dose (Day 1 to Day 28)
Reported as:
Mean · ug/mL
Adjusted Trough Nivolumab Serum Concentration at Steady-State (Cminss-Nivo) on Natural Logarithmic Scale
ug/mLNivo + Rela FDC SCNivo + Rela FDC IV
Adjusted Trough Nivolumab Serum Concentration at Steady-State (Cminss-Nivo) on Natural Logarithmic Scale4.759 ± 0.03354.169 ± 0.0330
Statistical analysis
  • Nivo + Rela FDC SC vs Nivo + Rela FDC IV · Adjusted mean difference: 0.591 · 90% CI 0.516 to 0.666
PrimaryAdjusted Trough Relatlimab Serum Concentration at Steady-State (Cminss-Rela) on Natural Logarithmic Scale

Blood samples were collected to assess serum concentration.

Time frame:
Pre-dose (Day 1 to Day 28)
Reported as:
Mean · ug/mL
Adjusted Trough Relatlimab Serum Concentration at Steady-State (Cminss-Rela) on Natural Logarithmic Scale
ug/mLNivo + Rela FDC SCNivo + Rela FDC IV
Adjusted Trough Relatlimab Serum Concentration at Steady-State (Cminss-Rela) on Natural Logarithmic Scale3.629 ± 0.05252.631 ± 0.0517
Statistical analysis
  • Nivo + Rela FDC SC vs Nivo + Rela FDC IV · Adjusted mean difference: 0.998 · 90% CI 0.880 to 1.116
SecondaryObjective Response Rate (ORR) by BICR

Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) by BICR
percentage of participantsNivo + Rela FDC SCNivo + Rela FDC IV
Objective Response Rate (ORR) by BICR43.0 (37.2 to 49.0)50.7 (44.8 to 56.6)
SecondaryDisease Control Rate (ORR) Per BICR

Disease control rate (DCR) is defined as the percentage of participants who achieve a BOR of confirmed Complete Response (CR), confirmed Partial Response (PR), or stable disease (SD), based on BICR assessments (using RECIST 1.1) divided by the number of all randomized participants. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Reported as:
Number · percentage of participants
Disease Control Rate (ORR) Per BICR
percentage of participantsNivo + Rela FDC SCNivo + Rela FDC IV
Disease Control Rate (ORR) Per BICR62.2 (56.3 to 67.9)72.3 (66.7 to 77.3)
SecondaryTime to Response (TTR) Per BICR

Time to response (TTR) assessed by BICR is defined as the time between the date of randomization and the first confirmed documented response (CR or PR) per RECIST 1.1 criteria. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Reported as:
Median · months
Time to Response (TTR) Per BICR
monthsNivo + Rela FDC SCNivo + Rela FDC IV
Time to Response (TTR) Per BICR2.79 (1.6 to 9.2)2.79 (1.4 to 17.7)
SecondaryDuration of Response (DoR) Per BICR

Duration of Response (DOR) in months is defined as the time from date of the first documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. CR is complete disappearance of all target lesions except nodal disease; all target nodes must decrease to normal size (short axis \< 10 mm). PR is ≥30% decrease under baseline of the sum of diameters of all target measurable lesions. Disease progression is defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Reported as:
Median · months
Duration of Response (DoR) Per BICR
monthsNivo + Rela FDC SCNivo + Rela FDC IV
Duration of Response (DoR) Per BICRNA (1.5 to 20.4)NA (1.6 to 20.3)
SecondaryProgression Free Survival Per BICR

Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Reported as:
Median · months
Progression Free Survival Per BICR
monthsNivo + Rela FDC SCNivo + Rela FDC IV
Progression Free Survival Per BICR12.65 (8.08 to NA)14.98 (12.12 to NA)
SecondaryObjective Response Rate (ORR) Per Investigator

Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on Investigator assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Per Investigator
percentage of participantsNivo + Rela FDC SCNivo + Rela FDC IV
Objective Response Rate (ORR) Per Investigator47.9 (42.0 to 53.9)52.4 (46.5 to 58.2)
SecondaryDisease Control Rate (ORR) Per Investigator

Disease control rate (DCR) is defined as the percentage of participants who achieve a BOR of confirmed Complete Response (CR), confirmed Partial Response (PR), or stable disease (SD), based on Investigator assessments (using RECIST 1.1) divided by the number of all randomized participants. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Reported as:
Number · percentage of participants
Disease Control Rate (ORR) Per Investigator
percentage of participantsNivo + Rela FDC SCNivo + Rela FDC IV
Disease Control Rate (ORR) Per Investigator62.2 (56.3 to 67.9)72.3 (66.7 to 77.3)
SecondaryTime to Response (TTR) Per Investigator

Time to response (TTR) assessed by Investigator is defined as the time between the date of randomization and the first confirmed documented response (CR or PR) per RECIST 1.1 criteria. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Reported as:
Median · months
Time to Response (TTR) Per Investigator
monthsNivo + Rela FDC SCNivo + Rela FDC IV
Time to Response (TTR) Per Investigator2.83 (1.4 to 12.9)2.79 (1.4 to 12.0)
SecondaryDuration of Response (DoR) Per Investigator

Duration of Response (DOR) in months is defined as the time from date of the first documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. CR is complete disappearance of all target lesions except nodal disease; all target nodes must decrease to normal size (short axis \< 10 mm). PR is ≥30% decrease under baseline of the sum of diameters of all target measurable lesions. Disease progression is defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Reported as:
Median · months
Duration of Response (DoR) Per Investigator
monthsNivo + Rela FDC SCNivo + Rela FDC IV
Duration of Response (DoR) Per InvestigatorNA (1.5 to 20.4)NA (1.6 to 20.3)
SecondaryProgression Free Survival Per Investigator

Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Reported as:
Median · months
Progression Free Survival Per Investigator
monthsNivo + Rela FDC SCNivo + Rela FDC IV
Progression Free Survival Per Investigator10.28 (6.57 to 14.98)14.82 (10.15 to NA)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from the first dosing date (or from randomization/on treatment) to the date of death from any cause. Median computed using Kaplan-Meier method.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 126 weeks)
Reported as:
Median · months
Overall Survival (OS)
monthsNivo + Rela FDC SCNivo + Rela FDC IV
Overall Survival (OS)NA (21.09 to NA)NA (NA to NA)
SecondaryTrough Serum Concentration of Nivolumab and Relatlimab (Cmind28) at Day 28

Blood samples were collected to assess serum concentration.

Time frame:
Pre-dose at Day 28
Reported as:
Geometric mean · ug/mL
Trough Serum Concentration of Nivolumab and Relatlimab (Cmind28) at Day 28
ug/mLNivo + Rela FDC SCNivo + Rela FDC IV
Relatlimab13.79 ± 705.10 ± 139
Nivolumab44.75 ± 4327.33 ± 48
SecondaryPeak Serum Concentration (Cmax1) After the First Dose of Nivolumab and Relatlimab

Blood samples were collected to assess serum concentration.

Time frame:
Post-dose Day 1
Reported as:
Geometric mean · ug/mL
Peak Serum Concentration (Cmax1) After the First Dose of Nivolumab and Relatlimab
ug/mLNivo + Rela FDC SCNivo + Rela FDC IV
Relatlimab32.62 ± 3646.70 ± 20
Nivolumab88.51 ± 35137.05 ± 24
SecondaryMaximum Observed Concentration at Steady State (Cmaxss) Nivolumab and Relatlimab

Blood samples were collected to assess serum concentration.

Time frame:
Post-dose Day 1
Reported as:
Geometric mean · ug/mL
Maximum Observed Concentration at Steady State (Cmaxss) Nivolumab and Relatlimab
ug/mLNivo + Rela FDC SCNivo + Rela FDC IV
Relatlimab71.58 ± 4465.42 ± 29
Nivolumab203.52 ± 41209.91 ± 27
SecondaryAverage Observed Concentration at Steady State (Cavgss) of Nivolumab and Relatlimab

Blood samples were collected to assess serum concentration.

Time frame:
Post-dose Day 1
Reported as:
Geometric mean · ug/mL
Average Observed Concentration at Steady State (Cavgss) of Nivolumab and Relatlimab
ug/mLNivo + Rela FDC SCNivo + Rela FDC IV
Relatlimab57.29 ± 4930.29 ± 53
Nivolumab164.02 ± 44106.33 ± 39
SecondaryNumber of Participants With Adverse Events, SAEs, AEs Leading to Discontinuation and Deaths

AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence at any dose that: results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity or substantial disruption of the ability to conduct normal life functions, results in a congenital abnormality or birth defect, or is an important medical event that may not result in death, be life-threatening, or require hospitalization, but may require medical or surgical intervention to prevent any of the outcomes listed above.

Time frame:
First dose (Day 1) and 30 days after last dose of study therapy (up to approximately 26 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events, SAEs, AEs Leading to Discontinuation and Deaths
ParticipantsNivo + Rela FDC SCNivo + Rela FDC IV
Death1110
Adverse Events275285
Serious Adverse Events109112
AEs leading to Discontinuation3947
SecondaryNumber of Participants With Immune-mediate Adverse Events (IMAEs)

AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment.

Time frame:
First dose (Day 1) and 135 days after last dose of study therapy (up to approximately 29 months)
Reported as:
Count of participants · Participants
Number of Participants With Immune-mediate Adverse Events (IMAEs)
ParticipantsNivo + Rela FDC SCNivo + Rela FDC IV
Pneumonitis26
Diarrhea/Colitis1712
Hepatitis1611
Nephritis/Renal Dysfunction41
Rash2521
Hypersensitivity17
SecondaryNumber of Participants With Other Event of Special Interest (OESI)

AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment.

Time frame:
First dose (Day 1) and 100 days after last dose of study therapy (up to approximately 28 months)
Reported as:
Count of participants · Participants
Number of Participants With Other Event of Special Interest (OESI)
ParticipantsNivo + Rela FDC SCNivo + Rela FDC IV
Myasthenic syndrome02
Demyelination event00
Guillain-Barre syndrome00
Pancreatitis event35
Uveitis event36
Encephalitis event34
Myocarditis event611
Myositis/rhabdomyolysis event52
Graft Versus Host Disease00
Autoimmune cytopenia10
Autoimmune eye disorder00
Immune mediated arthritis01
Other meningitis event02
SecondaryNumber of Participants With On-Treatment Worst CTCAE Grade 3-4 Laboratory Parameters

AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment.

Time frame:
First dose (Day 1) and 30 days after last dose of study therapy (up to approximately 26 months)
Reported as:
Count of participants · Participants
Number of Participants With On-Treatment Worst CTCAE Grade 3-4 Laboratory Parameters
ParticipantsNivo + Rela FDC SCNivo + Rela FDC IV
HEMOGLOBIN1210
PLATELET COUNT21
LEUKOCYTES, LOCAL LAB11
LYMPHOCYTES (ABSOLUTE), LOCAL LAB57
NEUTROPHILS (ABSOLUTE), LOCAL LAB32
ALKALINE PHOSPHATASE, LOCAL LAB02
ASPARTATE AMINOTRANSFERASE, LOCAL LAB34
ALANINE AMINOTRANSFERASE, LOCAL LAB35
BILIRUBIN, TOTAL, LOCAL LAB43
CREATININE, LOCAL LAB14
HYPERNATREMIA00
HYPONATREMIA54
HYPERKALEMIA12
HYPOKALEMIA14
HYPERCALCEMIA11
HYPOCALCEMIA12
HYPOGLYCEMIA10
SecondaryChange From Baseline Functional Assessment of Cancer Therapy -Melanoma (FACT-M) Total Score

The FACT-M questionnaire was used to assess the effects of disease symptoms on functioning and well-being. As a generic cancer-related core, the FACT-M includes the 27-item FACT General (FACT-G) to assess physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). In addition, the FACT-M includes a 16-item disease-specific Melanoma Subscale (MS). Each FACT-M item is rated on a 5-point scale ranging from 0 (not at all) to 4 (very much). Scores for the PWB, FWB, SWB, and EWB subscales can be combined to produce a FACT-G total score, which provides an overall indicant of generic quality of life, while the FACT-G and MS scores can be combined to produce a total score for the FACT-M, which provides a composite measure of general and targeted quality of life. Overall scale ranges from 0 to 172, higher values indicate better functioning as well as lower symptom burden.

Time frame:
Baseline (Day 1) and Week 85
Reported as:
Mean · Score on a scale
Change From Baseline Functional Assessment of Cancer Therapy -Melanoma (FACT-M) Total Score
Score on a scaleNivo + Rela FDC SCNivo + Rela FDC IV
Change From Baseline Functional Assessment of Cancer Therapy -Melanoma (FACT-M) Total Score9.76 ± 17.871.75 ± 15.33

Adverse events

Collected over All cause mortality were collected from Day 1 and up to approximately 29 months. SAEs and Non SAEs were collected from first dose (Day 1) and 135 days after last dose of study therapy (up to approximately 29 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivo + Rela FDC SC80/286 (28%)143/283 (50.5%)242/283 (85.5%)
Nivo + Rela FDC IV63/292 (21.6%)140/291 (48.1%)261/291 (89.7%)
Most frequent serious events
Showing 10 of 242
Most frequent serious events
EventNivo + Rela FDC SCNivo + Rela FDC IV
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)24/28323/291
ColitisGastrointestinal disorders10/2831/291
Adrenal insufficiencyEndocrine disorders9/2835/291
General physical health deteriorationGeneral disorders and administration site conditions3/2837/291
MyocarditisCardiac disorders5/2836/291
Atrial fibrillationCardiac disorders5/2831/291
PneumoniaInfections and infestations5/2834/291
Acute kidney injuryRenal and urinary disorders2/2835/291
Septic shockInfections and infestations4/2831/291
Troponin increasedInvestigations4/2832/291
Most frequent other events
Showing 10 of 39
Most frequent other events
EventNivo + Rela FDC SCNivo + Rela FDC IV
FatigueGeneral disorders and administration site conditions50/28376/291
PruritusSkin and subcutaneous tissue disorders59/28365/291
HypothyroidismEndocrine disorders59/28362/291
ArthralgiaMusculoskeletal and connective tissue disorders49/28355/291
DiarrhoeaGastrointestinal disorders53/28347/291
RashSkin and subcutaneous tissue disorders53/28347/291
AstheniaGeneral disorders and administration site conditions45/28350/291
NauseaGastrointestinal disorders46/28346/291
AnaemiaBlood and lymphatic system disorders43/28341/291
HeadacheNervous system disorders25/28339/291

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nivo + Rela FDC SCNivo + Rela FDC IVTotal
Mean64.3 ± 13.6063.1 ± 13.5863.7 ± 13.59
Age, Customized
Age, Customized(Participants)Nivo + Rela FDC SCNivo + Rela FDC IVTotal
18-64 years130147277
65-84 years150138288
85 years and over6713
Sex: Female, Male
Sex: Female, Male(Participants)Nivo + Rela FDC SCNivo + Rela FDC IVTotal
Female109120229
Male177172349
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivo + Rela FDC SCNivo + Rela FDC IVTotal
Hispanic or Latino5865123
Not Hispanic or Latino193209402
Unknown or Not Reported351853
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nivo + Rela FDC SCNivo + Rela FDC IVTotal
White239264503
Black or African-American437
Asian101
Multiple268
Unknown401959
08

Study locations

149 sites
  • Local Institution - 0125
    Phoenix, Arizona 85013, United States
  • Local Institution - 0189
    Springdale, Arkansas 72762, United States
  • Local Institution - 0098
    Los Angeles, California 90025, United States
  • Local Institution - 0093
    Orange, California 92868-3201, United States
  • Local Institution - 0123
    Stanford, California 94305, United States
  • Local Institution - 0113
    Englewood, Colorado 80113, United States
  • Local Institution - 0114
    Jacksonville, Florida 32224, United States
  • Local Institution - 0146
    Baltimore, Maryland 21201, United States
  • Local Institution - 0071
    Rochester, Minnesota 55905, United States
  • Local Institution - 0013
    Omaha, Nebraska 68130, United States
  • Local Institution - 0169
    Cleveland, Ohio 44195, United States
  • Local Institution - 0139
    Easton, Pennsylvania 18045, United States
  • Local Institution - 0124
    Philadelphia, Pennsylvania 19107, United States
  • Local Institution - 0122
    Murray, Utah 84107, United States
  • Local Institution - 0115
    Fairfax, Virginia 22031, United States
  • Local Institution - 0050
    Coffs Harbour, New South Wales 2450, Australia
  • Local Institution - 0175
    Orange, New South Wales 2800, Australia
  • Local Institution - 0172
    Port Macquarie, New South Wales 2444, Australia
  • Local Institution - 0118
    Wagga Wagga, New South Wales 2650, Australia
  • Local Institution - 0184
    Waratah, New South Wales 2298, Australia
  • Local Institution - 0033
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0055
    Wollstonecraft, New South Wales 2065, Australia
  • Local Institution - 0090
    Birtinya, Queensland 4575, Australia
  • Local Institution - 0008
    Bendigo, Victoria 3550, Australia
  • Local Institution - 0059
    Box Hill, Victoria 3128, Australia
  • Local Institution - 0154
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0030
    Melbourne, Victoria 3004, Australia
  • Local Institution - 0109
    Traralgon, Victoria 3844, Australia
  • Local Institution - 0106
    Nedlands, Western Australia 6009, Australia
  • Local Institution - 0161
    Nedlands, Western Australia 6009, Australia
  • Local Institution - 0027
    Graz, 8036, Austria
  • Local Institution - 0029
    Salzburg, 5020, Austria
  • Local Institution - 0168
    Sankt Pölten, 3100, Austria
  • Local Institution - 0037
    Vienna, 1090, Austria
  • Local Institution - 0072
    Brussels, 1200, Belgium
  • Local Institution - 0078
    Charleroi, 6000, Belgium
  • Local Institution - 0016
    Liège, 4000, Belgium
  • Local Institution - 0177
    Fortaleza, Ceará 60135237, Brazil
  • Local Institution - 0180
    Vitória, Espírito Santo 29043-260, Brazil
  • Local Institution - 0107
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Local Institution - 0110
    Rio de Janeiro, Rio de Janeiro 20220-410, Brazil
  • Local Institution - 0025
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Local Institution - 0031
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Local Institution - 0058
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Local Institution - 0002
    Porto Alegrelegre, Rio Grande do Sul 91350-250, Brazil
  • Local Institution - 0159
    Blumenau, Santa Catarina 89010-340, Brazil
  • Local Institution - 0009
    Barretos, São Paulo 14784-400, Brazil
  • Local Institution - 0018
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Local Institution - 0130
    São Paulo, São Paulo 01321-001, Brazil
  • Local Institution - 0141
    Calgary, Alberta T2N 5G2, Canada
  • Local Institution - 0121
    Hamilton, Ontario L8V 5C2, Canada
  • Local Institution - 0096
    Ottawa, Ontario K1H 8L6, Canada
  • Local Institution - 0116
    Toronto, Ontario M4N 3M5, Canada
  • Local Institution - 0103
    Québec, Quebec G1J 1Z4, Canada
  • Local Institution - 0143
    Temuco, Araucania 4800827, Chile
  • Local Institution - 0178
    Port Montt, Los Lagos Region 5507642, Chile
  • Local Institution - 0119
    Santiago, Providencia 7500653, Chile
  • Local Institution - 0140
    Recoleta, Santiago Metropolitan 8380455, Chile
  • Local Institution - 0144
    Santiago, Santiago Metropolitan 0101010, Chile
  • Local Institution - 0010
    Santiago, Santiago Metropolitan 7510032, Chile
  • Local Institution - 0074
    Santiago, Santiago Metropolitan 8150513, Chile
  • Local Institution - 0028
    Viña del Mar, Valparaiso 2520598, Chile
  • Local Institution - 0017
    Santiago, 7500921, Chile
  • Local Institution - 0083
    Prague, NY 128 00, Czechia
  • Local Institution - 0094
    Hradec Králové, 500 05, Czechia
  • Local Institution - 0091
    Olomouc, 77900, Czechia
  • Local Institution - 0082
    Ostrava Poruba, 708 52, Czechia
  • Local Institution - 0095
    Prague, 182 00, Czechia
  • Local Institution - 0164
    Helsinki, 00029, Finland
  • Local Institution - 0167
    Tampere, 33521, Finland
  • Local Institution - 0162
    Turku, 20520, Finland
  • Local Institution - 0108
    Toulouse, Cedex 9 31059, France
  • Local Institution - 0127
    Chambray-lès-Tours, Indre-Et-Loire 37044, France
  • Local Institution - 0111
    Lille, Nord 59000, France
  • Local Institution - 0063
    Nantes, OH 44093, France
  • Local Institution - 0061
    Villejuif, Val-De-Marne 94805, France
  • Local Institution - 0007
    Amiens, 80054, France
  • Local Institution - 0128
    Bayonne, 64100, France
  • Local Institution - 0022
    Bordeaux, 33000, France
  • Local Institution - 0129
    Clermont-Ferrand, 63003, France
  • Local Institution - 0046
    Dijon, 21079, France
  • Local Institution - 0117
    Marseille, 13385, France
  • Local Institution - 0052
    Pierre-Bénite, 69310, France
  • Local Institution - 0089
    Rennes, 35042, France
  • Local Institution - 0099
    Rouen, 76031, France
  • Local Institution - 0034
    Paris, Île-de-France Region 75475, France
  • Local Institution - 0101
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Local Institution - 0079
    Ulm, Baden-Wurttemberg 89081, Germany
  • Local Institution - 0011
    Regensburg, Bavaria 93042, Germany
  • Local Institution - 0003
    Lübeck, Schleswig-Holstein 23538, Germany
  • Local Institution - 0060
    Berlin, 10117, Germany
  • Local Institution - 0038
    Buxtehude, 21614, Germany
  • Local Institution - 0136
    Dortmund, 44137, Germany
  • Local Institution - 0039
    Erfurt, 99089, Germany
  • Local Institution - 0049
    Essen, 45147, Germany
  • Local Institution - 0166
    Frankfurt am Main, 60590, Germany
  • Local Institution - 0065
    Giessen, 35385, Germany
  • Local Institution - 0135
    Göttingen, 37075, Germany
  • Local Institution - 0138
    Hamburg, 20251, Germany
  • Local Institution - 0137
    Ludwigshafen, 67063, Germany

Showing the first 100 of 149 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Aug 2025, 28 months.

Results were first posted in Aug 2026, 1 year after primary completion.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 28 months is below that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2022
First posted
Nov 22, 2022
StartActual
Mar 6, 2023
Primary completionActual
Aug 4, 2025
CompletionEst.
Nov 18, 2027
Results first posted
Aug 26, 2026
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05625399
Responsible party
Sponsor
First posted
Nov 22, 2022
Start date
Mar 6, 2023
Primary completion
Aug 4, 2025
Completion
Nov 18, 2027 (estimated)
Results posted
Aug 26, 2026
Last update
Aug 26, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Relatlimab

Start the discussion